New drug cocktail targets tough lung cancer mutation
NCT ID NCT07339839
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a combination of two drugs—a targeted pill (Glecirasib) and an immunotherapy infusion (Ivonescimab)—as a first treatment for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The study will first find the safest dose of the combo, then check if it can shrink tumors. It involves 42 participants across multiple centers in China.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Glecirasib (a targeted pill) and Ivonescimab (an immunotherapy infusion)
- What this could lead to
- If it works, this could offer a new first-line treatment option for people with a specific type of advanced lung cancer (KRAS G12C mutation).
- What could go wrong
- This is a very early, small trial (Phase 1/2) with only 42 participants. The combination may cause serious side effects or fail to shrink tumors effectively.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS G12C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New antibody drug targets Cancer-Related fluid in the lungs
- New drug cocktail shows promise for Hard-to-Treat lung cancer
- New hope for drug-resistant lung cancer: combo therapy enters trial
- New scan may reveal who will benefit from immunotherapy
- Can extra immunotherapy stall advanced lung cancer?
- New hope for rare vascular malformations: targeted drugs enter trial